Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 5/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21452654 | 1.00 | MEN1 (0.44) | MEN1GAAKMT2APCSK9TDP1 | |
| SCHEMBL7759432 | 0.88 | MEN1 (0.42) | MEN1GAAKMT2APCSK9TDP1 | |
| SCHEMBL7758385 | 0.88 | MEN1 (0.42) | MEN1GAAKMT2APCSK9TDP1 | |
| SCHEMBL1105702 | 0.87 | PCSK9 (0.50) | MEN1GAAKMT2APCSK9TDP1 | |
| SCHEMBL6945578 | 0.86 | MEN1 (0.47) | MEN1GAAKMT2APCSK9TDP1 | |
| SCHEMBL1262597 | 0.86 | MEN1 (0.47) | MEN1GAAKMT2APCSK9TDP1 | |
| SCHEMBL4740871 | 0.86 | MEN1 (0.47) | MEN1GAAKMT2APCSK9TDP1 | |
| SCHEMBL24363894 | 0.84 | MEN1 (0.42) | MEN1GAAKMT2APCSK9TDP1 | |
| SCHEMBL3423364 | 0.84 | CYP2D6 (0.43) | MEN1GAAKMT2APCSK9TDP1 | |
| SCHEMBL19765482 | 0.83 | MEN1 (0.45) | MEN1GAAKMT2APCSK9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171469-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-05-29 | — | — | US | disclosed |
| US-20230312616-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312616-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312616-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-10-05 | — | — | US | disclosed |
| US-11414439-B2 | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210139514-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2021-05-13 | — | — | US | disclosed |
| US-20210032272-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-04 | — | — | US | disclosed |
| WO-2019200246-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | ABELA ALEXANDER RUSSELL (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019195739-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | ABELA ALEXANDER RUSSELL (US) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414439-B2 | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | CFTR, SCNN1G, CLCN2 | MEN1 4388/4885GAA 833/4885KMT2A 4639/4885 |
| US-20230312616-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | MEN1 4687/4885GAA 1503/4885KMT2A 4654/4885 |
| US-20210032272-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | CFTR, SCNN1G, CLCN2 | MEN1 4388/4885GAA 833/4885KMT2A 4639/4885 |
| US-20210139514-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | MEN1 4687/4885GAA 1503/4885KMT2A 4654/4885 |
| US-20250171469-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | MEN1 4687/4885GAA 1503/4885KMT2A 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.